ID: ALA2086480

Max Phase: Preclinical

Molecular Formula: C19H25N3O4S

Molecular Weight: 391.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=CC(=O)Nc1ccc(S(=O)(=O)N2CCN(C(=O)C3CCCC3)CC2)cc1

Standard InChI:  InChI=1S/C19H25N3O4S/c1-2-18(23)20-16-7-9-17(10-8-16)27(25,26)22-13-11-21(12-14-22)19(24)15-5-3-4-6-15/h2,7-10,15H,1,3-6,11-14H2,(H,20,23)

Standard InChI Key:  WAZOFYYWAQHTQZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 391.49

Molecular Weight (Monoisotopic): 391.1566

AlogP: 1.83

#Rotatable Bonds: 5

Polar Surface Area: 86.79

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.73

CX Basic pKa:

CX LogP: 1.76

CX LogD: 1.76

Aromatic Rings: 1

Heavy Atoms: 27

QED Weighted: 0.78

Np Likeness Score: -1.71

References

1. Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, Ichihara O, Felicetti B, Palan S, Pedret-Dunn A, Schaertl S, Sternberger I, Ebneth A, Scheel A, Winkler D, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Dominguez C, Wityak J..  (2012)  Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.,  55  (3): [PMID:22224594] [10.1021/jm201310y]

Source

Source(1):

• Scientific Literature